SFDA becomes first regulatory authority globally to approve registration of 'ZENBEXUS' to treat multiple myeloma in adults
RIYADH — The Saudi Food and Drug Authority (SFDA) has approved the registration of ZENBEXUS (iberdomide) for the treatment of adult patients with relapsed or refractory multiple myeloma in combination with daratumumab and dexamethasone. The SFDA is the first regulatory authority globally to approve the registration of this product.Multiple myeloma is a blood cancer originating in plasma cells…
Saudi Food and Drug Authority (SFDA) has become the first global regulatory body to endorse ZENBEXUS (iberdomide) for treating adult patients with relapsed or refractory multiple myeloma. This combination therapy, when used alongside daratumumab and dexamethasone, showed improved outcomes compared to standard treatments. Multiple myeloma, a blood cancer originating from plasma cells, can cause anemia, low white blood cell count, and weakened immunity, along with kidney issues and bone damage.
ZENBEXUS belongs to a class of drugs called cereblon E3 ligase modulators (CELMoD) agents, which work by promoting the destruction of proteins that support the survival and growth of multiple myeloma cells while boosting the immune system's ability to target these cells. The SFDA approved ZENBEXUS based on positive results from a Phase 3 clinical trial, noting that it was administered under specialized medical supervision with regular monitoring of patients' conditions and blood tests.
The approval underlines the SFDA's dedication to innovation and improving healthcare quality, aligning with Saudi Vision 2030.
Written by urgent.news from Saudi Gazette's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
